Unknown

Dataset Information

PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers.


ABSTRACT: Background: There has been evidence that Polybromo-1 (PBRM1) mutation was closely associated with immunotherapy response in clear cell renal cell carcinoma (ccRCC). However, it remains incompletely unclear whether PBRM1 mutations correlate with ICI response in pan-cancer. Methods: The clinical data and whole exome sequencing (WES) data were collected from seven published immunotherapy studies to evaluate the association between PBRM1 mutation and ICIs efficacy in the discovery cohort. In order to provide further insight into the relationship between PBRM1 and immunity, we analyzed a relatively large sample as a validation cohort. Moreover, we also collected the clinical data and mutation information of 134 non-small cell lung cancer (NSCLC) patients from the First Affiliated

SUBMITTER: Dai J 

PROVIDER: S-EPMC9868445 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature